Notes
The study received funding from Eli Lilly and Company, US.
Costs (2011 values) included those associated with drug acquisition, titration, all-cause discontinuation and the treatment of adverse events.
Reference
Wielage RC, et al. Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Applied Health Economics and Health Policy : 25 Apr 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0031-3
Rights and permissions
About this article
Cite this article
Duloxetine worth its cost for osteoarthritis pain. PharmacoEcon Outcomes News 678, 4 (2013). https://doi.org/10.1007/s40274-013-0386-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0386-6